- Home
- IMUX vs INVE Comparison
IMUX vs INVE Comparison
Compare IMUX & INVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMUX | INVE |
|---|---|---|
| Founded | 2016 | 1990 |
| Country | United States | United States |
| Employees | 66 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer peripheral equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.2M | 74.8M |
| IPO Year | 2013 | 1997 |
Fundamental Metrics
Financial Performance| Metric | IMUX | INVE |
|---|---|---|
| Price | $1.07 | $3.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $4.25 | ★ $5.50 |
| AVG Volume (30 Days) | ★ 2.9M | 59.9K |
| Earning Date | 02-26-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.00 | ★ 1182.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $60,219,000.00 |
| Revenue This Year | N/A | $11.25 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.21 |
| 52 Week Low | $0.51 | $2.86 |
| 52 Week High | $1.51 | $4.07 |
Technical Indicators
Market Signals| Indicator | IMUX | INVE |
|---|---|---|
| Relative Strength Index (RSI) | 50.46 | 43.30 |
| Support Level | $0.64 | N/A |
| Resistance Level | $1.17 | $3.69 |
| Average True Range (ATR) | 0.12 | 0.22 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 6.45 | 7.74 |
Price Performance
Historical ComparisonAbout IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.